- Home
- RMCF vs BLRX Comparison
RMCF vs BLRX Comparison
Compare RMCF & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | BLRX |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.6M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RMCF | BLRX |
|---|---|---|
| Price | $1.05 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 160.6K | 14.7K |
| Earning Date | 06-16-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $2.15 |
| 52 Week High | $2.99 | $5.05 |
Technical Indicators
Market Signals| Indicator | RMCF | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 54.03 |
| Support Level | N/A | $3.05 |
| Resistance Level | $1.79 | $3.51 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 28.47 | 49.57 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.